CALIBER - A phase II randomised feasibility trial of chemoablation with mitomycin versus surgical management in low risk non-muscle invasive bladder cancer release_dyhclrx7tjennn37ougwj3frra

by A. Hugh Mostafid, Nuria Porta, Joanne Cresswell, TRL Griffiths, John D Kelly, Steven R Penegar, Kim Davenport, John S McGrath, Nicholas Campain, Peter Cooke, Shikohe Masood, Margaret A Knowles (+5 others)

Published in BJU International by Wiley.

2020  

Abstract

To evaluate the activity of intravesical mitomycin C (MMC) to ablate recurrent low risk non-muscle invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for treatment of recurrence. CALIBER is a phase II feasibility study. Participants were randomised (2:1) to treatment with four once-weekly MMC 40mg intravesical instillations (chemoablation arm) or surgical management. The surgical group was included to assess feasibility of randomisation. The primary endpoint was complete response to intravesical MMC in the chemoablation arm at three months, reported with exact 95% confidence intervals. Secondary endpoints included time to subsequent recurrence, summarised by Kaplan-Meier methods. Between February 2015 and August 2017 82 patients with visual diagnosis of recurrent low risk NMIBC were enrolled from 24 UK hospitals (54 chemoablation, 28 surgical management). Median follow-up was 24 months. Complete response at three months was 37.0% (20/54; 95%CI: 24.3-51.3) with chemoablation and 80.8% (21/26; 95%CI 60.6-93.4) with surgical management. Amongst patients with complete response at three months, a similar proportion were recurrence-free by 12 months in both groups (84%). Amongst those with residual disease at three months, the 12-month recurrence-free proportion was lower in the surgical management group (40.0%) than in the chemoablation group (84%). Recruitment stopped early as chemoablation did not meet the pre-specified threshold of 45% complete responses at three months. Intravesical chemoablation in low risk NMIBC is feasible and safe, but did not demonstrate sufficient response in this trial. Following chemoablation there may be a reduction in recurrence rate, even in non-responders, that is greater than with surgery alone. Further research is required to investigate the role and optimal schedule of neo-adjuvant intravesical chemotherapy prior to surgery for NMIBC.
In text/plain format

Archived Files and Locations

application/pdf  319.5 kB
file_peojskgb75gzzn5yzwxmgcowcu
web.archive.org (webarchive)
eprints.whiterose.ac.uk (web)
application/pdf  319.5 kB
file_6m2jzcslyfhj3pgxfcv4vihk4q
web.archive.org (webarchive)
discovery.ucl.ac.uk (web)
Read Archived PDF
Archived
Type  article-journal
Stage   published
Date   2020-03-03
Language   en ?
DOI  10.1111/bju.15038
PubMed  32124514
Container Metadata
Not in DOAJ
In Keepers Registery
ISSN-L:  1464-4096
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: deb7659e-9031-42a2-ba2f-3f9e5ebefdb1
API URL: JSON